Platelet count and disease – editorial policy

Paul Harrison; Marie Lordkipanidzé; III Andrew L. Frelinger; Mark R. Thomas; Steve P. Watson

doi:10.1080/09537104.2020.1802002

Platelet count and disease – editorial policy

Paul Harrison
, Marie Lordkipanidzé
, III Andrew L. Frelinger
, Mark R. Thomas
, Steve P. Watson

Research output: Contribution to journal › Editorial

3 Citations (Scopus)

Original language	English
Pages (from-to)	969-970
Number of pages	2
Journal	Platelets
Volume	31
Issue number	8
Early online date	7 Aug 2020
DOIs	https://doi.org/10.1080/09537104.2020.1802002
Publication status	Published - 16 Nov 2020

Bibliographical note

Funding Information:
PH is a recipient of a research grant from Sysmex Japan. ML is a Fonds de recherche du Québec en Santé (FRQS) Junior 1 Research Scholar (33048); has received speaker fees from Bayer; has served on advisory boards for Servier; has participated in industry-funded trials from Idorsia; and has received in-kind and financial support for investigator-initiated grants from Leo Pharma, Roche Diagnostics and Aggredyne, for unrelated work. ALF has received support for investigator-initiated grants from argenx, BeiGene, Ionis, Ironwood, Pfizer, Surface Oncology, Sysmex America, and Takeda. SPW is on the Advisory Board of SUDA Pharmaceuticals.

Keywords

MPV
platelet
platelet counting

ASJC Scopus subject areas

Hematology

Access to Document

10.1080/09537104.2020.1802002

Cite this

@article{3da726bafed74aee9a62875fe8dc7e80,

title = "Platelet count and disease – editorial policy",

keywords = "MPV, platelet, platelet counting",

author = "Paul Harrison and Marie Lordkipanidz{\'e} and \{Andrew L. Frelinger\}, III and Thomas, \{Mark R.\} and Watson, \{Steve P.\}",

note = "Funding Information: PH is a recipient of a research grant from Sysmex Japan. ML is a Fonds de recherche du Qu{\'e}bec en Sant{\'e} (FRQS) Junior 1 Research Scholar (33048); has received speaker fees from Bayer; has served on advisory boards for Servier; has participated in industry-funded trials from Idorsia; and has received in-kind and financial support for investigator-initiated grants from Leo Pharma, Roche Diagnostics and Aggredyne, for unrelated work. ALF has received support for investigator-initiated grants from argenx, BeiGene, Ionis, Ironwood, Pfizer, Surface Oncology, Sysmex America, and Takeda. SPW is on the Advisory Board of SUDA Pharmaceuticals.",

year = "2020",

month = nov,

day = "16",

doi = "10.1080/09537104.2020.1802002",

language = "English",

volume = "31",

pages = "969--970",

journal = "Platelets",

issn = "0953-7104",

publisher = "Taylor \& Francis",

number = "8",

}

TY - JOUR

T1 - Platelet count and disease – editorial policy

AU - Harrison, Paul

AU - Lordkipanidzé, Marie

AU - Andrew L. Frelinger, III

AU - Thomas, Mark R.

AU - Watson, Steve P.

N1 - Funding Information: PH is a recipient of a research grant from Sysmex Japan. ML is a Fonds de recherche du Québec en Santé (FRQS) Junior 1 Research Scholar (33048); has received speaker fees from Bayer; has served on advisory boards for Servier; has participated in industry-funded trials from Idorsia; and has received in-kind and financial support for investigator-initiated grants from Leo Pharma, Roche Diagnostics and Aggredyne, for unrelated work. ALF has received support for investigator-initiated grants from argenx, BeiGene, Ionis, Ironwood, Pfizer, Surface Oncology, Sysmex America, and Takeda. SPW is on the Advisory Board of SUDA Pharmaceuticals.

PY - 2020/11/16

Y1 - 2020/11/16

KW - MPV

KW - platelet

KW - platelet counting

UR - https://doi.org/10.1080/09537104.2020.1802002

U2 - 10.1080/09537104.2020.1802002

DO - 10.1080/09537104.2020.1802002

M3 - Editorial

SN - 0953-7104

VL - 31

SP - 969

EP - 970

JO - Platelets

JF - Platelets

IS - 8

ER -